Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®)
Author:
- 1 May 2012
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 72 (7) , 987-1007
Abstract
Octocog alfa, antihaemophilic factor, plasma/albumin free method (Advate®) is a recombinant, human, full-length coagulation factor VIII that does not contain human- or animal-derived plasma proteins. It is indicated for the control and prevention of bleeding episodes, for perioperative management and for routine prophylaxis in children and adults with haemophilia A. This article reviews the pharmacological properties, therapeutic efficacy and tolerability of Advate® in these patients. In previously treated paediatric and adult patients with moderately severe or severe haemophilia A, Advate® administered prophylactically, on demand or during surgery was effective for the prevention and treatment of bleeding episodes in three pivotal, uncontrolled clinical trials. The haemostatic efficacy of Advate® in these trials was rated as ‘excellent’ or ‘good’ in most bleeding episodes, with the majority of episodes being managed with one infusion. These findings were supported by pooled analyses of clinical trials and routine clinical practice studies, including the Post-Authorization Safety Study. Additionally, in a comparative study, routine prophylaxis with Advate® administered in a standard regimen or in a pharmacokinetic-tailored regimen was effective for the prevention of bleeding episodes in patients with moderately severe or severe haemophilia A, with no significant difference between the two regimens in terms of efficacy. Moreover, any routine prophylaxis with Advate® was found to be more effective in preventing bleeding episodes than on-demand therapy with Advate®. Advate® was generally well tolerated in clinical trials and postmarketing studies, with the most common treatment-emergent adverse events being pyrexia and headache. Serious adverse events with Advate® therapy are development of high-titre factor VIII inhibitors (usually in previously untreated patients) and hypersensitivity reactions. As expected, the incidence of factor VIII inhibitors (any titre) appeared to be lower in previously treated patients (≤1.8%) than in previously untreated patients (≤20%). There are no head-to-head comparative trials of Advate® and other factor VIII concentrates. Nevertheless, current evidence indicates that Advate® is an effective option for the management of paediatric and adult patients with haemophilia A.Keywords
This publication has 48 references indexed in Scilit:
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New ChallengesSeminars in Thrombosis and Hemostasis, 2012
- Current Options and New Developments in the Treatment of HaemophiliaDrugs, 2011
- Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practiceHaemophilia, 2010
- Treatment of hemophilia: a review of current advances and ongoing issuesJournal of Blood Medicine, 2010
- Health economics in haemophilia: a review from the clinician’s perspectiveHaemophilia, 2010
- Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoringJournal of Thrombosis and Haemostasis, 2010
- Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJournal of Thrombosis and Haemostasis, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- ReFacto®1 and Advate®2: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia AHaemophilia, 2007